A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
A. J. Wagner
Consultant or Advisory Role - Genentech; Infinity; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech
J. C. Bendell
No relevant relationships to disclose
S. Dolly
No relevant relationships to disclose
J. A. Morgan
No relevant relationships to disclose
J. A. Ware
Employment or Leadership Position - Genentech
Stock Ownership - Roche
J. Fredrickson
Employment or Leadership Position - Genentech
Stock Ownership - Roche
K. E. Mazina
Employment or Leadership Position - Genentech
Stock Ownership - Roche
J. O. Lauchle
Employment or Leadership Position - Genentech
Stock Ownership - Roche
H. A. Burris
No relevant relationships to disclose
J. S. De Bono
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Arno Therapeutics; AstraZeneca; Exelixis; Genentech; GlaxoSmithKline; Merck; Novartis; Pfizer
Honoraria - Arno Therapeutics; AstraZeneca; Exelixis; Genentech; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Genentech